Loading...
Market
Will Novo Nordisk face a class-action lawsuit related to NAION risk from Ozempic or Wegovy by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Legal filings and news reports
Story
Harvard Study Links Ozempic, Wegovy to 6.7% Risk of Serious Eye Condition
Jul 3, 2024, 03:39 PM
A new study by Massachusetts Eye and Ear and Harvard has revealed a potential link between Novo Nordisk’s GLP-1 drugs, Ozempic and Wegovy, and a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. The study, published in JAMA Ophthalmology, found that patients prescribed these drugs for diabetes or weight loss had a higher risk of developing NAION compared to those not on the medication. The risk of optic neuropathy was 6.7% for the Ozempic group and 0.8% for the control group at 36 months. This is the first report of such an association, based on a matched cohort of approximately 17,000 individuals, highlighting the need for further research to understand the safety implications of these widely used medications.
View original story
Similar markets
Yes • 50%
No • 50%
No action taken • 25%
Warning issued • 25%
Recall issued • 25%
Label change required • 25%
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
Acknowledge risk and issue warning • 25%
Deny risk and continue marketing • 25%
Initiate further studies • 25%
Discontinue affected products • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Confirms link • 25%
Refutes link • 25%
Inconclusive • 25%
No publication • 25%
